Skip to main content
Anhui Huaheng Biotechnology Co., Ltd. logo

Anhui Huaheng Biotechnology Co., Ltd. — Investor Relations & Filings

Ticker · 688639 ISIN · CNE1000052M6 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 630 across all filing types
Latest filing 2026-03-17 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688639

About Anhui Huaheng Biotechnology Co., Ltd.

https://www.huahengbio.com/

Anhui Huaheng Biotechnology Co., Ltd. specializes in the research, development, and industrial production of bio-based products using synthetic biology and microbial fermentation technologies. The company is a global leader in the manufacturing of amino acids, notably L-alanine, DL-alanine, and β-alanine, as well as organic acids like succinic acid and other high-value biochemicals. Its product portfolio serves diverse sectors including food additives, animal nutrition, pharmaceuticals, personal care, and chemical synthesis. By leveraging advanced enzymatic catalysis and green manufacturing processes, the company provides sustainable alternatives to traditional chemical synthesis. Its operations focus on high-efficiency bioconversion and purification techniques to ensure product quality and environmental compatibility for a global customer base.

Recent filings

Filing Released Lang Actions
安徽华恒生物科技股份有限公司2025年度独立董事述职报告（陈继忠）
Board/Management Information Classification · 95% confidence The document is an independent director's annual performance report for the year 2025, detailing the director's duties, attendance, communication with shareholders, oversight of internal audits, and opinions on financial reports and company governance. It is a detailed narrative report on the director's activities and governance role rather than a financial report or announcement. It does not contain financial statements or earnings data, nor is it a regulatory announcement or certification. This type of document fits best under Board/Management Information (MANG), as it relates to management and board-level reporting on governance and director duties.
2026-03-17 Chinese
安徽华恒生物科技股份有限公司2025年年度报告
Annual Report Classification · 100% confidence The document is titled "安徽华恒生物科技股份有限公司2025 年年度报告" which translates to "Anhui Huaheng Biotechnology Co., Ltd. 2025 Annual Report." It contains detailed sections including company overview, management discussion and analysis, financial data, audit report mention, dividend distribution plan, governance, and comprehensive financial statements. The document length is substantial (15,000 characters) and includes actual financial data and analysis for the fiscal year 2025. It also includes auditor's unqualified opinion and signatures from company officers, which are typical components of a full annual report. Therefore, this document is the official yearly report covering company activity and full financial performance, matching the definition of an Annual Report (10-K). FY 2025
2026-03-17 Chinese
安徽华恒生物科技股份有限公司关于董事会对独立董事独立性自查情况的专项报告
Governance Information Classification · 95% confidence The document is a special report from the board regarding the independence of the company's independent directors, referencing compliance with relevant laws and regulations about independent directors. It is a governance-related disclosure about board members' independence, not a financial report, earnings release, or voting result. It does not announce a meeting or voting results, nor is it a proxy or remuneration report. The content fits best under Governance Information (CGR) as it details governance practices related to board independence.
2026-03-17 Chinese
安徽华恒生物科技股份有限公司募集资金存放、管理与实际使用情况鉴证报告
Audit Report / Information Classification · 88% confidence The document is a standalone assurance (verification) report prepared by an external CPA firm (RSM China) on the deposit, management and actual use of raised funds for Anhui Huaheng Biotechnology, including an auditor’s opinion, scope, findings and detailed tables. It is not an annual report or earnings release but a special audit report on use of proceeds. Therefore it fits the Audit Report / Information category. FY 2025
2026-03-17 Chinese
兴业证券股份有限公司关于安徽华恒生物科技股份有限公司2025年度募集资金存放与使用情况的核查意见
Regulatory Filings Classification · 85% confidence The document is a detailed special-purpose report on the storage and actual use of proceeds (‘募集资金存放与使用情况专项报告’) for 2025, prepared under China’s securities listing rules and verified by the sponsor and an accounting firm. It is not an earnings release, interim report, annual report, proxy, or other narrowly defined category. There is no Q&A or call transcript, no director dealings, no M&A, etc. It is a compliance filing containing substantive content rather than a simple announcement that a report is attached. As such, it best fits the “Regulatory Filings” category (RNS), which is the catch-all for miscellaneous compliance documents that do not fit more specific categories.
2026-03-17 Chinese
安徽华恒生物科技股份有限公司2025年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as "安徽华恒生物科技股份有限公司2025 年年度报告摘要" which translates to "Anhui Huaheng Biotechnology Co., Ltd. 2025 Annual Report Summary." It contains detailed financial data for the year 2025, including total assets, net profit, revenue, and quarterly financial data. It also includes management discussion and analysis, business overview, industry analysis, shareholder information, and dividend distribution plans. The document is over 10,000 characters long and contains substantive financial data and analysis, not just an announcement or summary. It is clearly a comprehensive annual report document rather than a brief announcement or a certification. Therefore, the document fits the definition of an Annual Report (10-K). FY 2025
2026-03-17 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.